| A02039 | |
|
|
|
| ¥66,623.00 | |
|
|
|
|
|
|
| Ask us a question | |
| Specificity | The product is specific for SARS-CoV-2 Nucleocapsid protein. |
| Host Species | Human |
| Immunogen | Recombinant SARS-CoV-2 Nucleocapsid Protein |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
|
|||||
| Form | Liquid |
| Storage Buffer | Supplied in PBS, pH 7.4, containing 0.02% sodium azide. |
| Concentration | 1 mg/ml |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. Avoid repeated freezing and thawing cycles. |
| Purification | Protein A affinity column |
| Isotype | Recombinant human IgG1 |
| Clonality | Monoclonal |
| Clone ID | HC2003 |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
| Target Background | SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). Nucleocapsid Protein is a most abundant structure protein of the coronavirus which is associated with nucleic acid.SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric is produced from cell culture in vitro under conditions free from animal-derived components. |
| Synonyms | 2019-nCoV Nucleocapsid Antibody (HC2003), SARS-CoV-2 NP Antibody |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
